SCHEMBL2219360

SCHEMBL2219360

O=c1[nH]c(-c2ccc(C(F)(F)F)cc2)nc2c1oc1ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 7/20 0.60
PIM3 Q86V86 7/20 0.60
CSNK2A2 P19784 6/20 0.60
CSNK2B P67870 6/20 0.60
PIM2 Q9P1W9 6/20 0.60
TNKS2 Q9H2K2 6/20 0.60
TNKS O95271 5/20 0.60
WNT3A P56704 3/20 0.60
PARP2 Q9UGN5 2/20 0.58
PARP1 P09874 2/20 0.58
ALDH1A1 P00352 1/20 0.52
GLA P06280 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MAPT P10636 1/20 0.50
PKM P14618 1/20 0.50
MAP4K4 O95819 1/20 0.50
CSNK1D P48730 1/20 0.50
CSNK2A1 P68400 1/20 0.50
DYRK1A Q13627 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6858209 0.81 TNKS2 (0.54) PIM1PIM3CSNK2A2CSNK2BPIM2
SCHEMBL2220413 0.78 PIM1 (0.55) PIM1PIM3CSNK2A2CSNK2BPIM2
SCHEMBL914340 0.78 MEN1 (0.53) PIM1PIM3CSNK2A2CSNK2BPIM2
SCHEMBL1852290 0.77 TNKS (0.63) PIM1PIM3CSNK2A2CSNK2BPIM2
SCHEMBL12439433 0.77 ALDH1A1 (0.57) PIM1PIM3CSNK2A2CSNK2BPIM2
SCHEMBL1853864 0.75 PIM1 (1.00) PIM1PIM3CSNK2A2CSNK2BPIM2
SCHEMBL11284110 0.75 TNKS (1.00) TNKS2TNKSWNT3APARP2PARP1
SCHEMBL7568265 0.73 TNKS (1.00) TNKS2TNKSWNT3APARP2PARP1
SCHEMBL15775279 0.73 TNKS (1.00) TNKS2TNKSWNT3APARP2PARP1
SCHEMBL2217397 0.72 SMN1; SMN2 (0.47) PIM1PIM3CSNK2A2CSNK2BPIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178107-A1 HCV PROTEASE INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2011-07-21 US disclosed
US-20110178107-A1 HCV PROTEASE INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2011-07-21 US disclosed
US-20110178107-A1 HCV PROTEASE INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178107-A1 HCV PROTEASE INHIBITORS HAVCR2, RNASE1, SERPINB1 PIM1 2408/4885PIM3 2176/4885CSNK2A2 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.